<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37471705</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0962</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Lupus</Title><ISOAbbreviation>Lupus</ISOAbbreviation></Journal><ArticleTitle>Characteristics of SLE patients with symptomatic COVID-19: Single centre experience at Sultan Qaboos University Hospital over a 30-month period.</ArticleTitle><Pagination><StartPage>1173</StartPage><EndPage>1178</EndPage><MedlinePgn>1173-1178</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">09612033231190717</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1177/09612033231190717</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">COVID-19 pandemic was declared by WHO in March 2020. Severity of disease varied from asymptomatic to fatal infection. Severe disease was found to be associated with hyperinflammation syndrome. Systemic lupus erythematosus (SLE) is treated with various immunosuppressive agents, intensity of which depends on the severity of the disease. We aimed to study the characteristic of SLE patients infected with COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">352 patients with SLE were included in this observational cross-section study conducted over a 30-month period beginning from 24<sup>th</sup> February 2020 (first COVID cases documented in Oman) until end of July 2022. Data were retrieved from electronic medical records and through questionnaire handed to patients in OPD or filled through phone calls.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">40.6% of SLE patients developed COVID-19 infection with mean age of 37&#xa0;years and maintaining their male to female ratio as in SLE disease. Majority of the patients in both COVID-infected and non-infected groups had SLE disease activity of zero. Sore throat and cough were present in almost all patients. Other common symptoms were myalgia/arthralgia (94%) followed by fever. Significant difference between the groups was in severity of SLE and in lung involvement. No difference was noted between the two groups in other parameters including regarding the frequency of medication.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This is the first study of COVID-19 in SLE patients in the Gulf Council Countries (GCCs). A significant difference between COVID-infected and uninfected groups was seen in the SLE disease activity and whether lung was involved in the SLE patients. We found no impact for DM, HTN, BMI, IHD, lupus nephrites of SLE medication on COVID-19 infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hassan</LastName><ForeName>Kowthar S</ForeName><Initials>KS</Initials><Identifier Source="ORCID">0000-0001-9902-3330</Identifier><AffiliationInfo><Affiliation>Sultan Qaboos University Hospital. Department of Medicine. Infectious Diseases Unit.</Affiliation><Identifier Source="RINGGOLD">194179</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Lawati</LastName><ForeName>Batool</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Sultan Qaboos University Hospital. Department of Medicine. Rheumatology Unit.</Affiliation><Identifier Source="RINGGOLD">37611</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rizvi</LastName><ForeName>Gauhar A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Sultan Qaboos University. College of Medicine. Family Medicine and Public Health.</Affiliation><Identifier Source="RINGGOLD">37611</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus</MedlineTA><NlmUniqueID>9204265</NlmUniqueID><ISSNLinking>0961-2033</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006761" MajorTopicYN="N">Hospitals</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">MMF</Keyword><Keyword MajorTopicYN="N">Oman</Keyword><Keyword MajorTopicYN="N">SLE</Keyword><Keyword MajorTopicYN="N">biologics</Keyword><Keyword MajorTopicYN="N">immunosuppression</Keyword><Keyword MajorTopicYN="N">steroids</Keyword></KeywordList><CoiStatement>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>20</Day><Hour>19</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>20</Day><Hour>16</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37471705</ArticleId><ArticleId IdType="pmc">PMC10359853</ArticleId><ArticleId IdType="doi">10.1177/09612033231190717</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cortegiani A, Ippolito M, Greco M, et al.Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review. Pulmonology 2021; 27(1): 52&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7369580</ArticleId><ArticleId IdType="pubmed">32713784</ArticleId></ArticleIdList></Reference><Reference><Citation>Polachek A, Gladman DD, Su J, et al.Defining low disease activity in systemic lupus erythematosus: low disease activity in SLE. Arthritis Care Res 2017; 69(7): 997&#x2013;1003.</Citation><ArticleIdList><ArticleId IdType="pubmed">27696791</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Iba&#xf1;ez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2000; 29(2).</Citation><ArticleIdList><ArticleId IdType="pubmed">11838846</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu XL, Qian Y, Jin XH, et al.COVID-19 in patients with systemic lupus erythematosus: a systematic review. Lupus 2022; 31(6): 684&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8990101</ArticleId><ArticleId IdType="pubmed">35382637</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchers AT, Naguwa SM, Shoenfeld Y, et al.The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev 2010; 9(5): A277&#x2013;A287.</Citation><ArticleIdList><ArticleId IdType="pubmed">20036343</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucchi D, Tani C, Elefante E, et al.Impact of first wave of SARS-CoV-2 infection in patients with Systemic Lupus Erythematosus: weighting the risk of infection and flare. PLoS One 2021; 16(1): e0245274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7806138</ArticleId><ArticleId IdType="pubmed">33439910</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Wang Y, Agostinis P, et al.Is hydroxychloroquine beneficial for COVID-19 patients? Cell Death Dis 2020; 11(7): 512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7341710</ArticleId><ArticleId IdType="pubmed">32641681</ArticleId></ArticleIdList></Reference><Reference><Citation>Araban M, Karimy M, Koohestani H, et al.Epidemiological and clinical characteristics of patients with COVID-19 in Islamic Republic of Iran. East Mediterr Health J 2022; 28(4): 249&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">35545905</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoong CWS, Amin MNME, Tan TC, et al.Viral arthralgia a new manifestation of COVID-19 infection? A cohort study of COVID-19-associated musculoskeletal symptoms. Int J Infect Dis 2021; 104: 363&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7813485</ArticleId><ArticleId IdType="pubmed">33476761</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozzalla Cassione E, Zanframundo G, Biglia A, et al.COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine. Ann Rheum Dis 2020; 79(10): 1382&#x2013;1383.</Citation><ArticleIdList><ArticleId IdType="pubmed">32398281</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathian A, Mahevas M, Rohmer J, et al.Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Ann Rheum Dis 2020; 79(6): 837&#x2013;839.</Citation><ArticleIdList><ArticleId IdType="pubmed">32332072</ArticleId></ArticleIdList></Reference><Reference><Citation>Giacomelli A, Pezzati L, Conti F, et al.Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection: a cross-sectional study. Clin Infect Dis 2020; 71(15): 889&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184514</ArticleId><ArticleId IdType="pubmed">32215618</ArticleId></ArticleIdList></Reference><Reference><Citation>AlRasheed MM, Fekih-Romdhane F, Jahrami H, et al.The prevalence and severity of insomnia symptoms during COVID-19: a global systematic review and individual participant data meta-analysis. Sleep Med 2022; 100: 7&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9359588</ArticleId><ArticleId IdType="pubmed">36030616</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F, Zheng S, Zheng C, et al.Attaching clinical significance to COVID-19-associated diarrhea. Life Sci 2020; 260: 118312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7443214</ArticleId><ArticleId IdType="pubmed">32846165</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahamat-Saleh Y, Fiolet T, Rebeaud ME, et al.Diabetes, hypertension, body mass index, smoking and COVID-19-related mortality: a systematic review and meta-analysis of observational studies. BMJ Open 2021; 11(10): e052777.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8557249</ArticleId><ArticleId IdType="pubmed">34697120</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Mawali A, Al-Harrasi A, Jayapal SK, et al.Prevalence and risk factors of diabetes in a large community-based study in the Sultanate of Oman: STEPS survey 2017. BMC Endocr Disord 2021; 21(1): 42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7934365</ArticleId><ArticleId IdType="pubmed">33673840</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Lawati J, Mabry RM, Al-Busaidi Z. Tobacco control in oman: it&#x2019;s time to get serious. Oman Med J 2017; 32(1): 3&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5187396</ArticleId><ArticleId IdType="pubmed">28042396</ArticleId></ArticleIdList></Reference><Reference><Citation>Walbi IA, Albarqi HA, Alghanim NS, et al.Effect of chronic hydroxychloroquine use on COVID-19 risk in patients with rheumatoid arthritis and systemic lupus erythematosus: a multicenter retrospective cohort. J Int Med Res 2022; 50(4): 3000605221090363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8998490</ArticleId><ArticleId IdType="pubmed">35387504</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez GA, Gerosa M, Beretta L, et al.COVID-19 in systemic lupus erythematosus: data from a survey on 417 patients. Semin Arthritis Rheum 2020; 50(5): 1150&#x2013;1157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7836639</ArticleId><ArticleId IdType="pubmed">32927376</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama S, Hamdeh S, Micic D, et al.Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: A systematic review and meta-analysis. Ann Rheum Dis 2021; 80(3): 384&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pubmed">33051220</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xfc;lsen A, K&#xf6;nig IR, Jappe U, et al.Effect of comorbid pulmonary disease on the severity of COVID&#x2010;19: a systematic review and meta&#x2010;analysis. Respirology 2021; 26(6): 552&#x2013;565.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8207055</ArticleId><ArticleId IdType="pubmed">33955623</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>